Symbiotec Pharmalab Ltd. has established the price band for its initial public offering in India [1], [2].
The move marks the company's entry into the public equity market, providing a benchmark for investors to evaluate the firm's valuation before the subscription period begins.
The company set the lower limit of the price band at ₹938 per share [1]. Reports on the upper limit vary between ₹988 per share [1] and ₹999 per share [2].
Investors can subscribe to the offering starting Aug. 24, 2024 [1]. The subscription window will remain open until Aug. 27, 2024 [1]. The company expects the shares to list on the stock exchange on Sept. 1, 2024 [1].
Symbiotec Pharmalab has detailed a specific allocation strategy for the shares. Qualified Institutional Buyers (QIBs) are allocated 50% of the offering [1]. Retail investors are designated 35% of the shares [1]. The remaining 15% are reserved for Non-Institutional Investors (NIIs) [1].
This distribution ensures that a significant portion of the offering is available to individual retail participants, while maintaining a strong institutional foundation. The listing date of Sept. 1, 2024 [1], will determine the initial market reception of the stock.
“The company set the lower limit of the price band at ₹938 per share.”
The allocation of 50% of shares to institutional buyers suggests Symbiotec Pharmalab is seeking stable, long-term capital from professional funds to anchor its market debut. By reserving 35% for retail investors, the company is also aiming for broad market visibility in the Indian pharmaceutical sector.
